Why Do Black Patients Fare Worse With Blood Cancer?
By Serena McNiff
HealthDay Reporter
FRIDAY, Dec. 11, 2020 (HealthDay News) A pair of studies shed new light on why a relatively rare blood cancer acute myeloid leukemia (AML) is more deadly among Black patients.
The takeaways: Where patients live and their access to quality health care matter. And even when Black people with AML have the same access to treatment as white patients, their survival is shorter something genetic differences might explain.
Authors of the two studies recently discussed their findings at an online news briefing held by the American Society of Hematology.
Model May Predict Post-treatment Hodgkin Lymphoma Outcomes medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
CRISPR Gene Editing Delivers Promise for Sickle-Cell Disease, Beta Thalassemia
CRISPR Therapeutics CEO Samarth Kulkarni, PhD
CRISPR Therapeutics and Vertex Pharmaceuticals have reported a consistent and sustained positive response in 10 patients treated for a pair of blood disorders sickle-cell disease (SCD) and beta thalassemia with their CRISPR-Cas9 gene-edited therapy CTX001 in a pair of Phase I/II trials. These are the first clinical studies of a CRISPR gene-editing candidate sponsored by U.S. companies.
According to data published last Saturday in the
New England Journal of Medicine (NEJM) and presented Sunday at the annual American Society of Hematology (ASH) Meeting and Exposition, all seven patients with transfusion-dependent beta thalassemia (TDT) including three who have either a severe or b0/b0 genotype were transfusion independent at the last follow-up in the TDT trial, which is known as CLIMB-111 (NCT03655678).
Why do Black patients fare worse with blood cancer than whites? medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
For patients with relapsed/refractory multiple myeloma (RRMM), teclistamab was found to have a manageable safety profile, according to data presented at the virtual American Society of Hematology conference.